Durgical
EN
Open the app

Other antianginals

Antianginals outside the nitrate, beta blocker and calcium channel blocker groups: ivabradine slows the sinus node; ranolazine blocks the late sodium current.

Updated

What they are

Second-line drugs added when angina or heart failure persists despite standard treatment, or when standard drugs are not tolerated. Ivabradine (If channel blocker) slows the heart rate without lowering blood pressure or contractility; ranolazine (late sodium current blocker) reduces angina without changing heart rate or blood pressure; trimetazidine shifts myocardial metabolism from fatty acids to glucose.

Mechanism of action

Ivabradine blocks HCN channels of the sinoatrial node, which carry the 'funny' pacemaker current If, so diastolic depolarisation is slower and the heart rate falls. Ranolazine inhibits the late inward sodium current; less sodium loading means less calcium overload through the sodium-calcium exchanger in ischaemic cells. Trimetazidine inhibits long-chain 3-ketoacyl-CoA thiolase in fatty acid beta-oxidation.

Target: HCN4 channel (If current), cardiac late sodium current (Nav1.5), 3-ketoacyl-CoA thiolase

Drugs in this class

Others in the class

  • Trimetazidine
  • Nicorandil

Test yourself

Think of the answer, then tap the question to see it.

Which current does ivabradine block and where?

The If 'funny' current carried by HCN channels in the sinoatrial node.

Why does ivabradine not help a patient in atrial fibrillation?

It acts only on the sinus node pacemaker; in atrial fibrillation the ventricular rate is set by the AV node.

Which antianginal reduces angina without changing heart rate or blood pressure?

Ranolazine, which blocks the late sodium current and limits calcium overload in ischaemic myocytes.

Add to my cards (3)

More Pharmacology questions →

← All of pharmacology

Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.

Sources: DailyMed - IVABRADINE tablet, film coated (DailyMed (U.S. National Library of Medicine), 2026); DailyMed - RANOLAZINE tablet, extended release (DailyMed (U.S. National Library of Medicine), 2026).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.